EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the … [Read more...]

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling pathways mediated by Stat3 (signal transducer and activator of transcription 3) play a primary role in diabetic retinopathy progression. This study tested CLT-005, a small molecule inhibitor of Stat3, for its dose-dependent therapeutic effects on vision loss in a rat model of diabetic … [Read more...]

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

"Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically associated with obesity, insulin resistance, type 2 diabetes (T2DM), and cardiovascular disease. In addition, patients with proliferative diabetic retinopathy (DR) have increased serum RBP4 levels compared to diabetic patients with mild or no retinopathy, which raises the possibility that RBP4 is … [Read more...]

New Skin Patch Monitors Glucose and Delivers Diabetes Drugs

People with diabetes need to closely monitor their blood glucose levels multiple times every day, usually using a device that pricks their finger for a blood test to assess whether they need insulin shots or other drugs. Since blood collection and shots can be painful, not all patients do it as regularly as they need to—which can lead to dangerous fluctuations in their blood glucose … [Read more...]

Research points towards new blindness prevention methods in diabetic eye disease

By combining data on optometry patient's eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. The results, reported in the journal PLOS Computational Biology, show precisely how a small protein that can both damage or grow blood vessels in the eye causes vision loss and blindness in people with diabetes. The study … [Read more...]

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing cause of blindness, with nearly 415 million diabetic patients at risk worldwide. The disease can be treated if detected early, but if not, it can lead to irreversible blindness.  A few years ago, a Google research team began studying whether machine learning could be used to screen for diabetic … [Read more...]

Cause of inflammation in diabetes identified

Inflammation is one of the main reasons why people with diabetes experience heart attacks, strokes, kidney problems and other, related complications. Now, in a surprise finding, researchers at Washington University School of Medicine in St. Louis have identified a possible trigger of chronic inflammation.  Through a series of experiments in the animals and in cell cultures, the researchers, … [Read more...]

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models

Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and mitogenic cytokine leptin can be implicated in ocular neovascularization and the other eye pathologies.  At least in part, leptin action appears to be mediated through functional interplay with vascular endothelial growth factor (VEGF).  The effects of VEGF on leptin expression were assessed in ocular endothelial cell … [Read more...]

Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification. Read the entire … [Read more...]

Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting.  To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment … [Read more...]

Preclinical Ophthalmic Contract Research